Abstract:Introduction: Two types of clinical resistance mutations, the C481S mutation, and BTK loss-of-activity mutations, have been identified to covalent (ibrutinib, acalabrutinib, and zanubrutinib) and non-covalent BTK inhibitors (pirtobrutinib). A safe and effective drug to treat patients who relapsed or were refractory to BTK inhibitor treatment is urgently needed. DZD8586 was designed to inhibit both BTK-dependent and BTK-independent BCR signaling pathways, with full blood-brain barrier (BBB) penetration. In the ongoing phase I/II studies (TAI-SHAN1, CTR20220558), DZD8586 demonstrated reasonable pharmacokinetic (PK) properties, safety profiles and preliminary anti-tumor activities in patients with relapsed or refractory (r/r) B-cell malignancies. Methods: The anti-tumor activities of DZD8586 were evaluated in pre-clinical cell and animal models driven by wildtype as well as various mutant BTKs. A healthy volunteer clinical study (TAI-SHAN2, NCT05176873) was conducted to investigate PK, pharmacodynamics (PD), and the safety of DZD8586, offering insight into the drug mechanism of action. The ongoing TAI-SHAN1 study in patients included dose escalation and extension cohorts. Patients with r/r B-NHL who failed systemic therapy were enrolled to determine its recommended phase II dose (RP2D). Different subtypes of B-cell Non-Hodgkin Lymphoma, including chronic lymphocytic leukemia (CLL) who failed BTK inhibitor treatment, central nervous system lymphoma (CNSL), follicular lymphoma (FL), marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL), are eligible. PD biomarkers were assessed. Results: DZD8586 showed equal potencies against wildtype and C481S mutant BTKs, as well as BTK mutations resistant to pirtobrutinib. In healthy subjects, exposure of DZD8586 increased approximately in a dose-proportional manner from 20 mg to 180 mg. Similar PK characteristics were observed between patients and healthy subjects with a half-life of ∼20 h. At the doses of ≥25 mg, near complete inhibition of pBTK was observed. A multinational dose escalation is ongoing. Patient characteristics: histological subtypes: FL, DLBCL, MZL, and MCL; median prior systemic therapies (range): 3 lines (2–6). Preliminary anti-tumor efficacies were observed in multiple B-NHL subtypes starting at 25 mg once daily. No patients experienced ≥ grade 3 treatment-related adverse events, per investigators’ assessment. Conclusion: DZD8586 is a promising investigational drug which could overcome BTK-dependent and BTK-independent resistance. In the ongoing clinical study, DZD8586 showed good safety profile and encouraging anti-tumor efficacy in heavily pre-treated r/r B-NHL patients. The updated data will be presented at the conference. Encore Abstract - previously submitted to ASCO 2023 Keyword: Molecular Targeted Therapies Conflicts of interests pertinent to the abstract Y. Bai Employment or leadership position: Dizal Pharmaceutical K. Fang Employment or leadership position: Dizal Pharmaceutical

Fig. S1 from the BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors

Supplemental Table S2 from the BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors

Supplemental Table S3 from the BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors

The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells

BIRB796, the Inhibitor of P38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells.

Supplementary Figure S4. Carfilzomib Overcomes Primary Ibrutinib Resistance in Vivo from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter

Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter.

Btk inhibitor combinations and multidrug-resistance

ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells

Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance

In Vitro, in Vivo and Ex Vivo Characterization of Ibrutinib: a Potent Inhibitor of the Efflux Function of the Transporter MRP1

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

A Non-Covalent Inhibitor XMU-MP-3 Overrides Ibrutinib-Resistant BtkC481S Mutation in B-cell Malignancies.

PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia

PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study

Supplementary Table 4 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL

Treatment of b‐cell malignancies with dzd8586 through overcoming both btk‐dependent and btk‐independent resistance